RDHL - レッドヒル・バイオファ―マ (Redhill Biopharma Ltd.) レッドヒル・バイオファ―マ

 RDHLのチャート


 RDHLの企業情報

symbol RDHL
会社名 Redhill Biopharma Ltd Ramat Gan (レッドヒル・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   レッドヒル・バイオファ―マは、イスラエルのバイオ製薬会社。胃腸癌を含む炎症性および胃腸疾患の治療用に、後期の臨床段階にある独自の経口投与薬剤を開発、買収に注力する。イスラエル、米国、カナダ、欧州で事業を展開。同社の製品パイプラインは、後期の臨床段階にある8薬の治療候補で構成される。   RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® for the treatment of travelers' diarrhea in adults. RedHill's key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (Yeliva®, ABC294640), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (v) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB-106, an encapsulated bowel preparation.
本社所在地 21 Ha'arba'a Street Tel-Aviv 64739 ISR
代表者氏名
代表者役職名
電話番号
設立年月日 40026
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 74人
url www.redhillbio.com
nasdaq_url https://www.nasdaq.com/symbol/rdhl
adr_tso 15297124
EBITDA EBITDA ー
終値(lastsale) 8.38
時価総額(marketcap) 128189899.12
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 RDHLのテクニカル分析


 RDHLのニュース

   RedHill Biopharma Ltd: RedHill Biopharma Announces Last Patient Out  2021/07/19 14:20:00 FinanzNachrichten
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-1
   Redhill Biopharma - ADR Shares Approach 52-Week Low - Market Mover  2021/07/17 00:30:01 Kwhen Finance
Redhill Biopharma - ADR (RDHL) shares closed today at 6.1% above its 52 week low of $5.90, giving the company a market cap of $260M. The stock is currently down 22.5% year-to-date, down 9.5% over the past 12 months, and down 45.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 17.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -40842.2% The company's stock price performance over the past 12 months lags the peer average by 74.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Redhill Biopharma - ADR Shares Approach 52-Week Low - Market Mover  2021/07/16 00:37:43 Kwhen Finance
Redhill Biopharma - ADR (RDHL) shares closed today at 1.0% above its 52 week low of $5.91, giving the company a market cap of $258M. The stock is currently down 23.0% year-to-date, down 2.5% over the past 12 months, and down 46.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.7%, and the S&P 500 rose 0.4%. Trading Activity Trading volume this week was 0.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1096.3% The company's stock price performance over the past 12 months lags the peer average by 322.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   RedHill Biopharma reports preliminary results from new preclinical study showing potent inhibition of COVID-19 variants by opaganib  2021/06/28 17:00:00 Proactive Investors
RedHill Biopharma Ltd. (NASDAQ:RDHL) has announced preliminary results from a new preclinical study showing potent inhibition of coronavirus (COVID-19) variants of concern by opaganib. Working with the University of Louisville Center for Predictive Medicine, opaganib was studied in a 3D tissue model of human bronchial epithelial cells (EpiAirway) to evaluate the in vitro efficacy of the treatment in inhibiting the Beta (South African) and Gamma (Brazilian) SARS-CoV-2 variants. Preliminary results showed opaganib strongly inhibited both Beta and Gamma variants. Opaganibs unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect against other emerging variants, including the Delta (Indian) variant. This expectation is due to the way opaganib exerts its antiviral effect, selectively inhibiting sphingosine kinase-2 (SK2) - a key enzyme produced in human cells that can be recruited by the virus to support its replication.
   RedHill Biopharma Releases Positive Data For Its Opaganib In Covid-19 Treatment  2021/06/28 12:00:19 Business Insider Markets
(RTTNews) - RedHill Biopharma Ltd. (RDHL) Monday said Opaganib, the company''s antiviral drug candidate for the treatment of Covid-19, showed strong inhibition against South African and Brazilian variants in preclinical study. Partnered with the University of Louisville Center for Predictive Medicine, opaganib was studied in a 3D tissue model of
   RedHill Biopharma to Present at the BIO Digital International Convention  2021/06/09 00:00:00 BioSpace
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that Mr. Adi Frish, RedHill''s Chief Corporate & Business Development Officer, will present a corporate overview at the BIO Digital International Convention, taking place June 14-18, 2021.
   RedHill completes enrollment in the global Phase 2/3 severe COVID-19 study with oral opaganib  2021/06/08 10:30:00 Proactive Investors
RedHill Biopharma Ltd. (NASDAQ:RDHL) said it has completed enrollment and randomized the last patient in the global Phase 2/3 study with oral opaganib in patients hospitalized with severe coronavirus (COVID-19) pneumonia positioning it as a frontrunner in the hunt for an oral pill to treat COVID-19. A total of 475 patients were randomized, more than the planned 464, with the primary endpoint of the study being the proportion of patients breathing room air without oxygen support by Day 14. Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, with dual anti-inflammatory and antiviral activity, that is host-targeted and is therefore expected to be effective against emerging viral variants. The company noted that the study also captures additional important outcome measures in the follow-up period of up to 6 weeks, such as the time to hospital discharge, improvement according to the World Health Organization Ordinal Scale for Clinical Improvement and incidence of intubation and mortality.
   Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Gilead Sciences (GILD) and RedHill Biopharma (RDHL)  2021/06/07 13:05:26 Smarter Analyst
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Gilead Sciences (GILD) and The post Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Gilead Sciences (GILD) and RedHill Biopharma (RDHL) appeared first on Smarter Analyst .
   RedHill Biopharma completes enrollment in phase 2/3 opaganib COVID-19 study  2021/06/07 12:40:03 Seeking Alpha
   RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study  2021/06/07 00:00:00 BioSpace
The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464
   RedHill Biopharma to Present at the BIO Digital International Convention  2021/06/09 00:00:00 BioSpace
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that Mr. Adi Frish, RedHill''s Chief Corporate & Business Development Officer, will present a corporate overview at the BIO Digital International Convention, taking place June 14-18, 2021.
   RedHill completes enrollment in the global Phase 2/3 severe COVID-19 study with oral opaganib  2021/06/08 10:30:00 Proactive Investors
RedHill Biopharma Ltd. (NASDAQ:RDHL) said it has completed enrollment and randomized the last patient in the global Phase 2/3 study with oral opaganib in patients hospitalized with severe coronavirus (COVID-19) pneumonia positioning it as a frontrunner in the hunt for an oral pill to treat COVID-19. A total of 475 patients were randomized, more than the planned 464, with the primary endpoint of the study being the proportion of patients breathing room air without oxygen support by Day 14. Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, with dual anti-inflammatory and antiviral activity, that is host-targeted and is therefore expected to be effective against emerging viral variants. The company noted that the study also captures additional important outcome measures in the follow-up period of up to 6 weeks, such as the time to hospital discharge, improvement according to the World Health Organization Ordinal Scale for Clinical Improvement and incidence of intubation and mortality.
   Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Gilead Sciences (GILD) and RedHill Biopharma (RDHL)  2021/06/07 13:05:26 Smarter Analyst
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Gilead Sciences (GILD) and The post Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Gilead Sciences (GILD) and RedHill Biopharma (RDHL) appeared first on Smarter Analyst .
   RedHill Biopharma completes enrollment in phase 2/3 opaganib COVID-19 study  2021/06/07 12:40:03 Seeking Alpha
   RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study  2021/06/07 00:00:00 BioSpace
The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464

 関連キーワード  (― 米国株 レッドヒル・バイオファ―マ RDHL Redhill Biopharma Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)